134 related articles for article (PubMed ID: 34652050)
21. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
22. Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array.
Völker HU; Weigel M; Strehl A; Frey L
Diagn Pathol; 2018 Aug; 13(1):67. PubMed ID: 30170623
[TBL] [Abstract][Full Text] [Related]
23. 19. Male breast cancer: aetiology, genetics and clinical management.
Tischkowitz MD; Hodgson SV; Fentiman IS
Int J Clin Pract; 2002 Dec; 56(10):750-4. PubMed ID: 12510948
[TBL] [Abstract][Full Text] [Related]
24. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
[TBL] [Abstract][Full Text] [Related]
25. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
26. Mutations in BRCA2 and PALB2 in male breast cancer cases from the United States.
Ding YC; Steele L; Kuan CJ; Greilac S; Neuhausen SL
Breast Cancer Res Treat; 2011 Apr; 126(3):771-8. PubMed ID: 20927582
[TBL] [Abstract][Full Text] [Related]
27. uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial.
Annecke K; Schmitt M; Euler U; Zerm M; Paepke D; Paepke S; von Minckwitz G; Thomssen C; Harbeck N
Adv Clin Chem; 2008; 45():31-45. PubMed ID: 18429492
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
29. Male breast cancer.
Joseph A; Mokbel K
Int J Fertil Womens Med; 2004; 49(5):198-9. PubMed ID: 15633473
[TBL] [Abstract][Full Text] [Related]
30. Male breast cancer: risk factors, diagnosis, and management (Review).
Johansen Taber KA; Morisy LR; Osbahr AJ; Dickinson BD
Oncol Rep; 2010 Nov; 24(5):1115-20. PubMed ID: 20878100
[TBL] [Abstract][Full Text] [Related]
31. BRCA2 gene mutations in Slovenian male breast cancer patients.
Besic N; Cernivc B; de Grève J; Lokar K; Krajc M; Novakovic S; Zgajnar J; Teugels E
Genet Test; 2008 Jun; 12(2):203-9. PubMed ID: 18439106
[TBL] [Abstract][Full Text] [Related]
32. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
[TBL] [Abstract][Full Text] [Related]
33. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
Tai YC; Domchek S; Parmigiani G; Chen S
J Natl Cancer Inst; 2007 Dec; 99(23):1811-4. PubMed ID: 18042939
[TBL] [Abstract][Full Text] [Related]
34. BRCA2 carriers with male breast cancer show elevated tumour methylation.
Deb S; Gorringe KL; Pang JB; Byrne DJ; Takano EA; ; Dobrovic A; Fox SB
BMC Cancer; 2017 Sep; 17(1):641. PubMed ID: 28893223
[TBL] [Abstract][Full Text] [Related]
35. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
[TBL] [Abstract][Full Text] [Related]
36. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
37. Dachshund 1 is Differentially Expressed Between Male and Female Breast Cancer: A Matched Case-Control Study of Clinical Characteristics and Prognosis.
Cui Q; Kong D; Li Z; Ahiable P; Wang K; Wu K; Wu G
Clin Breast Cancer; 2018 Oct; 18(5):e875-e882. PubMed ID: 29478945
[TBL] [Abstract][Full Text] [Related]
38. Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer.
Castelló R; Estellés A; Vázquez C; Falcó C; España F; Almenar SM; Fuster C; Aznar J
Clin Chem; 2002 Aug; 48(8):1288-95. PubMed ID: 12142386
[TBL] [Abstract][Full Text] [Related]
39. Breast cancer in men.
Giordano SH; Buzdar AU; Hortobagyi GN
Ann Intern Med; 2002 Oct; 137(8):678-87. PubMed ID: 12379069
[TBL] [Abstract][Full Text] [Related]
40. CYP17 promoter polymorphism and breast cancer risk in males and females in relation to BRCA2 status.
Gudmundsdottir K; Thorlacius S; Jonasson JG; Sigfusson BF; Tryggvadottir L; Eyfjord JE
Br J Cancer; 2003 Mar; 88(6):933-6. PubMed ID: 12644832
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
